Renaissance Capital logo

SpringWorks Therapeutics Priced, Nasdaq: SWTX

Phase 3 biotech developing small molecule therapies for rare cancers.

Industry: Health Care

Latest Trade: $18.00 0.00 (0.0%)

First Day Return: n/a

Return from IPO: 0.0%

Industry: Health Care

We are a clinical-stage biopharmaceutical company applying a precision medicine approach to acquiring, developing and commercializing life-changing medicines for underserved patient populations suffering from devastating rare diseases and cancer. We have a differentiated portfolio of small molecule targeted oncology product candidates and are advancing two potentially registrational clinical trials in rare tumor types, as well as several other programs addressing highly prevalent, genetically defined cancers. Our most advanced product candidate, nirogacestat, is an oral, small molecule gamma secretase inhibitor, or GSI, initially in development for the treatment of desmoid tumors, a rare and often debilitating and disfiguring soft tissue tumor for which there are currently no therapies approved by the FDA. We believe nirogacestat may address the significant limitations associated with existing treatment options and has the potential to become the first therapy approved by the FDA for both newly diagnosed and previously treated desmoid tumors. Since we licensed nirogacestat from Pfizer in August 2017, the FDA granted nirogacestat both Orphan Drug Designation and Fast Track Designation for this indication. In May 2019, we announced the initiation of the DeFi trial, a potentially registrational Phase 3 clinical trial of nirogacestat for patients with desmoid tumors. We expect to provide an update on the DeFi trial in 2020 ahead of an anticipated top-line data readout in 2021.
more less
IPO News for SpringWorks Therapeutics
more
IPO Data
IPO File Date 08/16/2019
Offer Price $18.00
Price Range $16.00 - $18.00
Offer Shares (mm) 9.0
Deal Size ($mm) $162
Lock-Up Date IPO Pro Only
Street Research IPO Pro Only
IPO Data
IPO Date 09/12/2019
Offer Price $18.00
Price Range $16.00 - $18.00
Offer Shares (mm) 9.0
Deal Size ($mm) $162
Lock-Up Date IPO Pro Only
Street Research IPO Pro Only
Underwriters
more
Company Data
Headquarters Stamford, CT
Founded 2017
Employees 52
Website www.springworkstx.com